Blood borne infections (BBIs) are viruses that are carried in the blood, specifically hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). They can be transmitted through sexual contact, sharing needles, needle-stick injuries, from mother to baby during pregnancy, during birth or through breast feeding.
HBV
WHO estimates that 296 million people were living with chronic hepatitis B infection in 2019, with 1.5 million new infections each year.
In 2019, hepatitis B resulted in an estimated 820 000 deaths, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer).
HCV
Globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year. There are an estimated 3.2 million adolescents and children with chronic hepatitis C infection.
WHO estimated that in 2019, approximately 290 000 people died from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer).
HIV
There were an estimated 38.4 million people living with HIV at the end of 2021, two thirds of whom (25.6 million) are in the WHO African Region.
In 2021, 650 000 people died from HIV-related causes and 1.5 million people acquired HIV.
WHO presented Global health sector strategies 2022-2030, substantially increase access to hepatitis B and hepatitis C testing to reach people living with chronic HBV and HCV infection, of whom more than 80% and 90%, respectively, are currently undiagnosed.
UNAIDS released Fast Track: Ending the AIDS epidemic by 2030. 95% of people living with HIV know their HIV status; 95% of people who know their status on treatment; and 95% of people on treatment with suppressed viral loads.
Sansure, specialist in hepatitis virus and HIV molecular diagnostics. Since 2008, Sansure has developed HBV DNA, HCV RNA, HIV-1 RNA Quantitative Fluorescence Diagnostic Kit with the foresight which agrees with WHO to provide patients living with HBV/HCV/HIV infection with an affordable, accessible and sustainable alternative to diagnose HBV/HCV/HIV, monitor disease progression, and assess the stage of Blood-borne Infections disease and eligibility for treatment.
